Animal Antibiotics and Antimicrobials Market - Trends Forecast Till 2028

Market Overview

The global Animal Antibiotics and Antimicrobials Market is growing with the CAGR of 6.85% in the forecast period of 2021 to 2028 and is expected to reach USD 10.37 billion by 2027.

The term antibiotic or antimicrobial is used for those agents who kill or inhibit the growth of microorganism. The antimicrobials products have significant benefits to the animal and to human food safety. There are researches, which have proven that an increase in the rate of animal illness results in higher rate of human illness. Therefore, livestock dealers depend on animal antibiotics to provide safe food.

The factors such as the growing need for the animal-derived food products, the growing of the prevalence of the zoonotic diseases, the applications of the guidelines for stopping the spread of the animal diseases and the increasing need for the pet insurance and the rising of the animal health expenses are some of the factors that have supported long-term expansion for Animal Antibiotics and Antimicrobials Market.

Regional Analysis

North America dominates the animal antibiotics and antimicrobials market because of the increasing number of companion animal healthcare spending, cumulative demand for animal-derived food products, and occurrence of various food-producing. Furthermore, increasing alertness about zoonotic diseases will further boost the growth of the animal antibiotics and antimicrobials market in the region.

Insights are provided for each region and major countries within the regions

Competitive Landscape

Key Players

• Zoetis
• Boehringer Ingelheim International GmbH
• Merck & Co., Inc.
• Ceva, Eli Lilly and Company
• Bayer AG
• Dechra Pharmaceuticals PLC
• Virbac, Vetoquinol S.A
• Boehringer Ingelheim GmbH
• Sanofi
• Bioniche Animal Health
• Elanco
• Fort Dodge Animal Health

Recent Developments

• September 2020, Zoetis announced the launch of Vetscan Imagyst™, a diagnostic platform that uses a combination of image recognition technology, algorithms and cloud-based artificial intelligence (AI) to deliver accurate testing results to the clinic.
• June 29, 2021 - Sanofi will invest approximately €400 million annually in a first-of-its kind vaccines mRNA Center of Excellence. The Center will work to accelerate the development and delivery of next-generation vaccines by bringing together approximately 400 dedicated employees integrating end-to-end mRNA vaccine capabilities with dedicated R&D, digital, and chemistry, manufacturing and controls (CMC) teams across sites at Cambridge, MA (US) and Marcy l’Etoile, Lyon (France).

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
• Gain authentic and granular data access for Animal Antibiotics and Antimicrobials Market so as to understand the trends and the factors involved behind changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope